ASH 2023 | Hypertension prevalence in CLL and how it is affected by acalabrutinib treatment
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses hypertension as a comorbidity and adverse event (AE) of the BTK inhibitor (BTKi) acalabrutinib in patients with chronic lymphocytic leukemia (CLL). A cumulative analysis of clinical trial data revealed that hypertension is a common comorbidity in patients with CLL, but it is not worsened by acalabrutinib treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics/Janssen, TG Therapeutics, AstraZeneca, Caribou Biosciences, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Epizyme, ADC Therapeutics, BeiGene, Morphosys, Bristol Myers Squibb, Merck, Abbvie; Research Funding: Pharmacyclics/Janssen, Sunesis Pharmaceuticals, Nurix, AstraZeneca, Fate Therapeutics, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Curis, Inc, Epizyme, CRISPR Therapeutics, Bristol Myers Squibb, Merck, Adaptive Biotechnologies; Speakers Bureau: TG Therapeutics, AstraZeneca, Kite, Bristol Myers Squibb.
